Amgen's $0.55B Volume Ranks 139th as Lung Cancer Trial Kicks Off

On August 21, 2025, Amgen (AMGN) traded with a volume of $0.55 billion, ranking 139th in market activity. The stock closed down 0.23%, reflecting modest pressure amid broader market dynamics.

Amgen announced the initiation of a Phase 1b clinical trial evaluating the combination of Tarlatamab and AB248 for extensive-stage small cell lung cancer. The study, conducted in collaboration with Asher Biotherapeutics, aims to determine the safety, tolerability, and optimal dosing of the drug pair. The trial is non-randomized and unmasked, with an estimated start date of August 29, 2025. This development highlights Amgen’s ongoing focus on advancing oncology therapies in a competitive landscape with limited treatment options for advanced lung cancer.

The study’s potential to establish a novel therapeutic approach could influence investor sentiment, particularly if interim data demonstrate favorable safety profiles or efficacy signals. However, the trial is in its early stages and not yet recruiting participants, meaning near-term impacts on Amgen’s stock may remain limited. The biotech sector’s broader momentum, including analyst ratings and price targets for peers, underscores the importance of Amgen’s pipeline progress in maintaining its market position.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered a 1-day return of 1.98%, with a total return of 7.61% over 365 days. The approach had a Sharpe ratio of 0.94 but experienced a maximum drawdown of -29.16%, reflecting market volatility risks.